Back

Precise Control of Switchable Chimeric Antigen Receptor T Cells Allows Enhanced Safety and Less T Cell Exhaustion

Zhang, Z. A.; Herring, L.; Shwe, T. H.; Hu, Y.; Song, X.; Cao, W.; Liu, W. R.

2025-12-10 cancer biology
10.64898/2025.12.07.692875 bioRxiv
Show abstract

Chimeric antigen receptor (CAR)-T cell therapies have achieved remarkable success in treating hematologic malignancies, yet their clinical utility remains limited by safety concerns, poor persistence, and T-cell exhaustion driven by continuous receptor signaling. Although switchable CAR systems offer external control, most existing designs are irreversible, binary, or compromising CAR-T potency. Here, we introduce a chemically switchable CAR platform that enables graded, reversible regulation of CAR-T activity while retaining full therapeutic capacity. Using engineered CAR-T cells, we evaluate drug-controlled activation, cytotoxicity, and cytokine release against CD19 tumor cells and screened clinically approved NS3/4A inhibitors to identify optimal small-molecule controllers. Compared with conventional CAR-T cells, switchable CAR-T cells exhibited minimal background activity in the OFF state, preventing antigen-driven activation and cytokine release in the absence of drug. Upon drug addition, CAR expression was rapidly restored, with full-length CAR detectable within 1 hour and [~]80% of maximal expression achieved by 4 hours. Reversible suppression of CAR expression protected normal CD19 B cells once malignant cells were eliminated, addressing the clinical challenge of persistent CD19 CAR-T activity that can lead to B-cell aplasia, hypogammaglobulinemia, and recurrent infections. Furthermore, switchable CAR-T cells displayed reduced exhaustion, enhanced persistence, stable CAR expression, and preferential central memory differentiation following tumor clearance. Together, these findings establish the switchable CAR-T system as a next-generation, reversible, and clinically compatible CAR-T platform. Key PointsO_LIOptimized switchable CAR enables precise control of functional CAR expression, T-cell activation, cytokine release, and cytotoxicity. C_LIO_LIExternal regulation of CAR-T cells enhances safety and promotes sustained persistence in chronic stimulation models. C_LI

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
Nature Communications
5641 papers in training set
Top 19%
9.5%
2
Science Advances
1243 papers in training set
Top 2%
7.1%
3
Cell Reports Medicine
153 papers in training set
Top 0.2%
6.1%
4
Molecular Therapy Oncology
10 papers in training set
Top 0.1%
6.1%
5
Journal for ImmunoTherapy of Cancer
75 papers in training set
Top 0.5%
5.4%
6
Cancer Cell
42 papers in training set
Top 0.2%
5.4%
7
Cell Reports
1498 papers in training set
Top 8%
5.0%
8
Cancer Discovery
66 papers in training set
Top 0.9%
2.4%
9
Cancer Immunology Research
35 papers in training set
Top 0.4%
2.3%
10
Molecular Therapy
81 papers in training set
Top 0.8%
2.1%
50% of probability mass above
11
Theranostics
37 papers in training set
Top 0.4%
2.1%
12
eLife
5828 papers in training set
Top 45%
2.1%
13
iScience
1154 papers in training set
Top 14%
2.1%
14
Cell Chemical Biology
94 papers in training set
Top 0.7%
1.9%
15
Nature Cancer
39 papers in training set
Top 0.8%
1.9%
16
Nature Biomedical Engineering
47 papers in training set
Top 0.7%
1.7%
17
Cell
431 papers in training set
Top 6%
1.7%
18
PLOS Pathogens
820 papers in training set
Top 7%
1.5%
19
Signal Transduction and Targeted Therapy
30 papers in training set
Top 0.4%
1.5%
20
Communications Biology
993 papers in training set
Top 18%
1.4%
21
Clinical Cancer Research
64 papers in training set
Top 1%
1.3%
22
npj Precision Oncology
53 papers in training set
Top 1%
1.1%
23
Cell Stem Cell
62 papers in training set
Top 1%
1.1%
24
Advanced Science
286 papers in training set
Top 7%
1.1%
25
Journal of Hematology & Oncology
10 papers in training set
Top 0.3%
1.0%
26
Molecular Cancer Therapeutics
40 papers in training set
Top 0.7%
1.0%
27
Cancer Letters
35 papers in training set
Top 0.9%
1.0%
28
Proceedings of the National Academy of Sciences
2444 papers in training set
Top 39%
1.0%
29
Science Translational Medicine
127 papers in training set
Top 4%
0.8%
30
Blood
74 papers in training set
Top 1%
0.8%